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Prevalence of medication-related falls in
200 consecutive elderly patients with hip
fractures: a cross-sectional study
Charlotte Uggerhøj Andersen1,2,3*, Pernille Overgaard Lassen4, Hussain Qassim Usman4, Nadja Albertsen4,
Lars Peter Nielsen1,3 and Stig Andersen2,4
Abstract
Background: Hip fractures constitute a major health problem in elderly people and are often fall-related. Several
factors can contribute to a fall episode leading to hip fracture, including fall-risk-increasing drugs (FRIDs), which are
often used by elderly people.
We aimed to investigate the prevalence of medication-related falls and to assess the role of FRIDs and potentially
inappropriate medications (PIMs) in a population of elderly patients hospitalized for a hip fracture.
Methods: We reviewed the patient records of 200 consecutive patients, aged ≥65 years, who were admitted for a
hip fracture and evaluated whether medications were likely to have contributed to the fall episode. PIMs were
identified using the Screening Tool of Older Persons’ Prescriptions version 2 (STOPP) and by evaluating indications,
contra-indications and interactions of the prescribed medications for each patient.
Results: FRIDs were used by 175 patients (87.5%). Medications were considered a likely contributor to the fall in 82
patients (41%). These were most often psychotropic medications alone or in combination with antihypertensives
and/or diuretics. The 82 patients with suspected medication-related falls used more medications, FRIDs and PIMs
than the rest of the patients, and in 74 (90%) of the 82 patients, at least one medication considered to be a
contributor to the fall was also a PIM.
Conclusions: The prevalence of suspected medication-related falls was 41%. It seems likely that a medication
review could have reduced, though not eliminated, the risk of falling in this group of patients.
Keywords: Fall-risk-increasing drugs, Potentially inappropriate medication, Fall, Polypharmacy, Geriatrics
Background
A hip fracture is associated with considerable socio-
economic costs [1] and constitutes a high-risk situation
for an elderly patient, as the mortality for patients older
than 65 years is 12–35% within the first year after the
fracture [2] and remains elevated for several years [3].
Several medications have been identified as fall-risk-
increasing drugs (FRIDs) [4–8]. The association between
an increased risk of falling and the use of psychotropic
medications, such as antidepressants, antipsychotics and
benzodiazepines, seems well established, as indicated by
odds ratios ranging from 1.3 to 2 in a recent metanalysis
[8]. The association between falls and the use of cardio-
vascular medications, including antihypertensives and
antiarrhythmics, does not seem quite as consistent [6].
However, in clinical practice, cardiovascular medications
are often regarded as FRIDs, [9, 10] as their adverse
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effects can directly or indirectly cause dizziness,
hypotension and orthostatic hypotension. Several reports
have shown that more than 90% of elderly people experi-
encing a fall or a hip fracture are taking FRIDs [10, 11].
Thus, FRIDs can be regarded as a modifiable risk factor.
Furthermore, a recent study showed that 85% of elderly
patients with a hip fracture were prescribed potentially
inappropriate medications (PIMs), which may be un-
necessary or entail a high risk of adverse effects [12].
The Screening Tool of Older Persons’ Prescriptions
(STOPP) [13] may guide the performance of a medica-
tion review, both by pointing out situations in which
certain medications are potentially inappropriate and by
identifying certain FRIDs as PIMs.
Given the high prevalence of FRIDs and PIMs among
elderly patients, it may be hypothesized that medication
reviews and interventions to reduce FRIDs and PIMs in
this group would effectively reduce the risk of falling.
However, two recent randomized studies investigating
the effect of FRID-withdrawal among more than 600 eld-
erly people experiencing a fall [9], and the effect of
medication reviews [14] among 199 elderly patients with
hip fractures [14] did not find an effect of these inter-
ventions on the rate of falls during a 12-month follow-
up period. Possible explanations include competing risk
factors for falling, such as comorbidities, and impaired
cognition, balance, or vision. In addition, extrinsic fac-
tors influencing the subject [15, 16] may play a role in
many falls.
Even though the prevalence of FRID users among pa-
tients with a hip fracture is high, it is not known how
often FRIDs actually contribute to the fall. This know-
ledge is essential to understanding how much the inci-
dence of hip fracture could potentially be reduced by
stopping the use of these medications. Thus, the aims of
our study were to estimate the prevalence of
medication-related falls leading to a hip fracture in a
population of elderly patients admitted to a joint ortho-
paedic and geriatric ward and to assess the role of FRIDs
and PIMs.
Methods
Study design and population
This study was a retrospective cross-sectional study.
Two hundred consecutive patients with hip fracture,
aged 65 years or older, admitted to a Danish University
Hospital during a period of 24 weeks in 2017 were iden-
tified by a search in the hospital’s database using the
ICD-10 codes for fracture of the femur (DS72-DS729).
Evaluation and definition of medication-related falls,
FRIDs and PIMs
A consultant in Clinical Pharmacology (CUA) reviewed
all patient records, focusing on 1) the description of the
fall episode, including fall-related symptoms and the
conclusions regarding the causes of the fall, made by the
attending geriatrician during admission; 2) comorbidi-
ties, demographic data and medication list at the time of
admission; 3) blood pressure, respiratory frequency, per-
ipheral saturation, body temperature and heart rate at
the time of and during admission; 4) laboratory data in-
cluding c-reactive protein, leucocyte count, electrolytes,
haemoglobin, liver and renal parameters, and blood
glucose; 5) the results of other diagnostic evaluations
performed during admission; and 6) medication with-
drawals or changes during admission.
FRIDs were defined in accordance with previous work
on fall-risk-related medications [6–8, 13, 17, 18]: 1) psy-
chotropic medications (antidepressants, antipsychotics,
antiepileptic medications, medications for Parkinson’s
disease, medications for dementia, first-generation anti-
histamines, benzodiazepines or benzodiazepine-like
medications (zopiclone and zolpidem) and opioids); 2)
cardiovascular medications (calcium antagonists, angio-
tensin converting enzyme (ACE)-inhibitors, angiotensin-II
receptor (AT-II) antagonists, beta-adrenoceptor antago-
nists, alpha-adrenoceptor antagonists, diuretics, nitrous
vasodilators, and anti-arrhythmic medications); and 3)
urinary antispasmodics. PIMs were identified by review of
the patients’ medication lists according to the STOPP ver-
sion 2, [13] available from the Danish Geriatric Society.
Furthermore, the indications, contra-indications and inter-
actions for each prescribed medication, as listed in the
Summary of Product Characteristics found on the home-
page of the Danish Medicines Agency, were also consid-
ered for each patient. All data mentioned above was
entered in case report forms during the initial review.
The clinical pharmacologist excluded a suspected
medication-related fall if a patient had not experienced a
fall, was not using any medications or FRIDs, or if a non-
medication-related fall cause was described in the patient
record. Otherwise, the clinical pharmacologist and a con-
sultant in Geriatrics (POL, HU, or NA) discussed the case
in order to obtain a consensus about whether one or more
medications were likely contributors to the fall. Medica-
tions were generally considered likely contributors to the
fall if their effects, adverse effects or interactions could
have caused or aggravated symptoms or clinical findings
related to the fall episode, for example, orthostatic
hypotension. If we concluded that medications were likely
contributors to the fall, we defined the patient as having
had a suspected medication-related fall. If the fall was
more likely explained by the consequences of acute or
chronic disease, tripping or extrinsic factors, we did not
consider medications likely contributors. Patients who
were not attended by an on-site geriatrician during admis-
sion were evaluated retrospectively following the same
procedure as that used for the rest of the patients.
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Data handling and statistical analysis
Study data were collected and managed using REDCap
(Vanderbilt, USA) electronic data capture tools hosted at
Aalborg University. REDCap is a secure, web-based ap-
plication designed to support data capture for research
studies [19]. Data were exported for statistical analysis
or graphics in STATA (StataCorp. 2017. Stata Statistical
Software: Release 15. College Station, TX: StataCorp
LLC). The distribution of variables was evaluated ac-
cording to histograms and Q-norm plots, and data that
had a normal distribution were summarized as means ±
standard deviations (SDs). Variables that were not nor-
mally distributed were summarized by medians [25th
percentile, 75th percentile], and differences between two
groups were tested by the Wilcoxon rank-sum test. Dif-
ferences in the prevalence of diseases between patients
with and without a suspected medication-related fall
were analysed by two-sample z-test. Differences in age,
clinical data and the number of medications and FRIDs
among multiple groups were analysed by regression with
a bootstrap analysis. The differences between propor-
tions of patients with PIMs among multiple groups were
compared by pairwise two-sample z-tests. Power calcula-
tion to estimate study size was not performed due to
lack of data to support this. Analyses were performed
without imputation of missing data. The number of pa-
tients with missing data are indicated for each variable
in footnotes of tables. Percentages of patients with a
given condition (e.g. sodium < 132mmol/l) were calcu-
lated by dividing the number of confirmed cases with
the total number of patients in the population (200).
Results
Prevalence of suspected medication-related falls
A fall preceded the hip fracture in 197 (98.5%) patients,
and the fall was considered a low energy trauma, indicat-
ing an osteoporotic fracture, in 175 (87.5%) patients.
Three patients (1.5%) (group 1) did not experience a fall,
and eight (4%) (group 2) did not take any medication. In
59 patients (29.5%) (group 3), the fall episode seemed
more likely to have been caused by an extrinsic factor,
such as a push by a large animal or another person, or
tripping. Consequences of a chronic or acute disease,
such as influenza, urinary tract infection or uncontrolled
atrial fibrillation, were considered the main cause of the
fall in 48 patients (24%) (group 4). Finally, we considered
82 (41%) patients as having had a suspected medication-
related fall (group 5) (Fig. 1). The most frequent reason
for medications to be regarded as a contributor to the
fall was dizziness in patients using medications with diz-
ziness as a known adverse effect (n = 21 (10.5%)),
followed by the presence of low blood pressure or symp-
toms of orthostatic hypotension in patients who were
using medications able to decrease blood pressure (n =
17 (8.5%)). Medications were suspected to contribute to
a fall by impairing the functional level in 12 patients
(6%) and to contribute to accidental happenings leading
to a fall by influencing cognition or balance in 11 pa-
tients (5.5%). In both instances, psychotropic drugs were
the most commonly involved. Diuretics were thought to
play a role by inducing hyponatremia in four patients
(2%). Finally, the circumstances of the fall episode were
not well described in 17 patients (8.5%), but the presence
of FRIDs and no other obvious causes of the fall led us
to define these as having had a suspected medication-
related fall.
A consultant geriatrician had performed an onsite
evaluation of 170 (85%) of the patients in the study
population during admission.
Demographics, comorbidities and use of medication in
the total population
A summary of the populations’ demographic and clinical
characteristics is shown in Table 1.
One or more comorbidities were present in 195
(97.5%) patients, and the most common comorbidities
were hypertension, osteoporosis and atrial fibrillation
(Table 2).
The median number of prescribed medications used at
admission was seven, ranging from 0 to 27. At least 1
FRID was prescribed to 175 (87.5%) patients, and the
median number of used FRIDs was three, ranging from
zero to seven. A detailed list of medications used at the
time of admission is available in Table 1S in the on-line
supplementary material.
Characteristics of patients with a suspected medication-
related fall
The group of patients with a suspected medication-
related fall was markedly older than the group in which
an extrinsic factor or tripping was considered the most
likely reason (group 3). Otherwise, only the number of
prescribed medications and FRIDs at the time of admis-
sion and the proportion of PIMs were significantly
higher in patients with a suspected medication-related fall
than in patients in the other groups (Table 3). Regarding
comorbidities, patients with a suspected medication-
related fall had a higher prevalence of osteoporosis and
ischaemic heart disease when compared to the rest of the
patients (Table 2).
Medications playing a role in the fall episode
One medication was considered likely to play a role
in the fall episode in 16 (19.5%) patients, and more
than one medication was considered likely to a role
in the fall episode in 66 (80.5%) of the 82 patients
with a suspected medication-related fall. All medica-
tions suspected to contribute to falls were FRIDs.
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Psychotropic medications, including antidepressants,
benzodiazepines, benzodiazepine-like medications, an-
tipsychotics, antiepileptics and opioids, were suspected
of contributing in 68 (83%) patients, whereas antihy-
pertensive medications and diuretics likely played a
role in 30 (36.5%) and 29 (35%) of the 82 patients
with a suspected medication-related fall, respectively.
The medication subclasses likely to have contributed
to the fall episodes in more than five patients are
shown in Fig. 2.
PIMs.
PIMs were identified in 141 patients (70.5%). Among pa-
tients with a suspected medication-related fall, PIMs were
identified in 79 (96%) patients compared to 62 (52%) of
the 118 patients without a suspected medication-related
fall (p < 0.001). In 74 (90%) of the 82 patients with a sus-
pected medication-related fall (37% of the total popula-
tion), PIMs were suspected to have contributed directly to
the fall leading to admission. A single medication was con-
sidered both a PIM and a contributor to the fall in 36
(44%) patients, and more than one medication was consid-
ered a PIM and contributor to the fall in 38 (46%) of the
82 patients with a suspected medication-related fall. In 42
(51%) of the patients with a suspected medication-related
fall, the number of medications found likely to be involved
in the fall episode was higher than the number of identi-
fied PIMs.
Discussion
We found that the prevalence of suspected medication-
related falls leading to hip a fracture among elderly
Fig. 1 Main causes of falls. Figure 1. Flow diagram showing the selection procedure for the patients having a medication-related fall, as evaluated
with the joint expertise of a clinical pharmacologist and a geriatrician
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patients was 41%. Furthermore, we identified at least
one of the medications found to contribute to the fall as
potentially inappropriate in 90% of patients with a sus-
pected medication-related fall.
The clinical data point to an influence of factors other
than medication, e.g., extrinsic sources or chronic or
acute illness, in the incident leading to a hip fracture in
more than half of the patients. However, the estimated
41% prevalence of suspected medication-related falls
suggests that medications are a major risk factor. We
have not identified other studies estimating the preva-
lence of medication-related falls in hip fracture patients,
and we were expecting a higher occurrence of suspected
medication-related falls due to the frequent use of FRIDs
in hip fracture patients [10, 11]. Medications can be con-
sidered modifiable risk factors, and we identified an
overlap between medications found to contribute to the
fall episode and medications identified as PIMs in the
majority of the patients with a suspected medication-
related fall. Interestingly, the number of medications
suspected to be involved in the fall episode was often
higher than the number identified as PIMs. Hence, a
medication review may reduce the risk of medication-
related falls but cannot eliminate it in all at-risk patients,
suggesting that the prevalence of potentially avoidable
medication-related fall-induced hip fractures might be
markedly lower than 41%. This suggests that trials ex-
ploring the effect of medication reviews either requires a
very large number of participants with falls or should be
targeted at high risk groups. Our data may guide studies
on the latter. In line with this, it has yet to be proven
that withdrawal of medications reduces the risk of falls
[9, 14, 20]. The randomized study by Boye et al. [9]
showed that withdrawal of FRIDs did not alter the fall
rate or number of FRIDs after 12 months, and they pro-
posed a lack of compliance with the withdrawal or pre-
scription of new medications as possible explanations
[9]. Accordingly, the number of FRIDs may actually in-
crease after a hip fracture, [21] indicating that medica-
tion reviews among elderly patients should be a primary
prophylactic modality. To select patients in whom to
perform a medication review, our data points towards
patients prescribed a higher number of medications and
FRIDs, as these were the only obvious risk factors that
detected those individuals with a suspected medication-
related fall. The finding of a higher prevalence of ischae-
mic heart disease and previous fractures may be explained
by an association of these conditions with a higher usage
of medications.
We found that the most common FRIDs associated with
suspected medication-related falls were psychotropic medi-
cations, particularly selective serotonin reuptake inhibitors
and benzodiazepines or benzodiazepine-like medications,
followed by antihypertensives and diuretics. This can be
Table 1 Characteristics of the study population
General characteristics
Female (n (%)) 136 (68)
Age (years) 82 [76,88]
Age > 80 years (n (%)) 115 (57.5)
Height (cm) 166 ± 9 cm
Weight (kg) 67 ± 14 kg
Body mass index (kg/m2) 24 ± 4
Body mass index < 18.5 (n (%)) 17 (8.5)
Residence (n (%))
Private home 158 (79)
Nursing home 35 (17.5)
Other 9 (4.5)
Type of fall and fracture (n (%))
Low-energy trauma defining an
osteoporotic fracture
175 (87.5)
Not low-energy trauma 22 (11)
No fall 3 (1.5)
Clinical findings (n (%))
First SBP at admission < 120mmHg 12 (6)
Lowest measured SBP during
the admission < 120mmHg
135 (67.5)
First PS at admission < 90% 22 (11)
First RF at admission > 20 /min 23 (11.5)
First TP > 38.0 °C 11 (5.5)
Abnormal laboratory findings at
the time of admission (n (%))
Estimated glomerular filtration
rate* < 60 ml/min
74 (37)
Estimated glomerular filtration
rate* < 30 ml/min
13 (6.5)
C-reactive protein > 100mg/l 12 (6)
Haemoglobin < 6mmol/l 11 (5.5)
Sodium < 132mmol/l 12 (6)
Potassium < 3.2 mmol/l 5 (2.5)
Thyroid stimulating hormone
< 0.3 m IU/l or > 4.5 mIU/l
20 (10)
Alanine amino transferase
> 50 U/l in men or > 35 U/l in women
12 (6)
Glucose < 4 mmol/l 0 (0)
Glucose > 10 mmol/l 14 (7)
Albumin < 34 g/l 69 (34.5)
Table 1. Detailed description of the characteristics of the study population.
Abbreviations: CNS central nervous system SBP systolic blood pressure, PS
peripheral saturation, RF respiratory frequency, TP body temperature. *:
calculated by the EPI-CKD formula. Number of patients with missing data for
each variable: age: 0, height: 10, weight: 17, body mass index: 24, first SBP: 2,
lowest SBP: 8, PS: 4, RF: 4, TP: 8, Estimated glomerular filtration rate: 1, c-
reactive protein: 9, Haemoglobin: 3, sodium: 2, potassium: 2, thyroid
stimulating hormone: 37, alanine amino transferase: 8, glucose: 16, albumin: 2.
Percentages of patients with a given condition (e.g. sodium < 132mmol/l)
were calculated by dividing the number of confirmed cases with the total
number of patients in the population (200)
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explained by the known adverse effects of these drugs
[6, 8] and their widespread use. Thus, it is important to
focus on these medications when performing medica-
tion reviews in order to reduce the risk of medication
related falls. Nevertheless, thiazides may also have a
beneficial effect on bone strength by increasing renal
calcium reabsorption [22]. The use of medications with
an established bone-demineralizing effect, such as oral
corticosteroids, aromatase inhibitors and enzyme-
inducing anti-epileptics, was infrequent in our popula-
tion, suggesting a limited contribution to falls by these
medications among hip fracture patients. However, we
could not evaluate the lifetime use of medications, and
the long-term effect of prior use of such medications
cannot be excluded in our study.
This study has several limitations. For one thing, the
population is relatively small. The retrospective design
implies that we had to rely on data obtained routinely
and the possibility of focused examinations and inter-
views was precluded. The evaluation of clinical data and
falls was not blinded to the list of medications, and the
evaluations of the role of medications may have varied
depending on the observer. On the other hand, the
retrospective design [23] allowed us to study an
unselected population of consecutive elderly patients
with hip fractures, with access to clinical data, laboratory
data and a detailed description of the fall episode. The
validity of the description of the fall episode in the pa-
tient record is strengthened by the fact that this is a des-
ignated clinical task for the on-site consultant in
geriatrics. Furthermore, the joint expertise of the clinical
pharmacologist and the geriatrician in the evaluation of
the individual patient records strengthens the evaluations
and conclusions in our report. The female preponderance,
age, high frequency of comorbidities, widespread use of
medications, FRIDs, and PIMs in our patients corres-
pond well to those from other studies of Danish and
international cohorts of patients with hip fractures
[11, 12, 24–26]. Thus, our population may be a repre-
sentative sample of elderly patients with hip fracture.
Altogether, we consider our result to be a qualified
estimate of the prevalence of medication-related falls
in elderly hip fracture patients.
Conclusions
The prevalence of suspected medication-related falls was
41% in elderly patients admitted with a hip fracture. It







P value (patients with vs.
without a medication-related fall)
n (%) 200 (100) 118 (59) 82 (41)
Prevalence of comorbidity (n (%))
Hypertension 90 (45) 49 (42) 41 (50) 0.2
Osteoporosis 46 (23) 28 (24) 18 (22) 0.8
Atrial fibrillation 44 (22) 21 (18) 23 (28) 0.09
Previous ischaemic stroke 36 (18) 21 (18) 14 (17) 0.9
Chronic obstructive pulmonary disease 32 (16) 16 (13) 16 (19) 0.2
Dementia 30 (15) 15 (13) 15 (18) 0.3
Previous fracture (hip or spine) 29 (14.5) 12 (10) 17 (20) 0.04
Ischaemic heart disease 27 (13.5) 11 (9) 20 (24) 0.04
Type 2 diabetes 27 (13.5) 19 (14) 8 (10) 0.4
Chronic renal failure 25 (12.5) 16 (13) 9 (11) 0.6
Depression 22 (11) 9 (7) 13 (16) 0.07
Cancer 18 (9) 12 (10) 6 (7) 0.5
Chronic heart failure 14 (7) 10 (8) 4 (5) 0.3
Visual or hearing impairment 14 (7) 13 (7) 10 (7) 0.9
Hyperthyreosis 12 (6) 7 (6) 5 (6) 1
Arthrosis 12 (6) 6 (5) 5 (6) 0.7
Hypothyreosis 10 (5) 6 (5) 4 (5) 1
Chronic alcoholism 10 (5) 5 (4) 4 (5) 1
Table 2. Comorbidities at the time of admission with a prevalence of 5 % or higher. One patient could have several diagnoses. Differences between patients with
and without a medication-related fall were tested by the two-sample z-test
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Table 3 Comparison of demographics, clinical parameters and use of medications for the groups 1 to 5 shown in Fig. 1
Group no.
1 2 3 4 5 p-value
(regression
with bootstrap)
n (%) 3 (1.5) 8 (4) 59 (29.5) 48 (24) 82 (41)








Age (years) 78 [77–84] 72 [70–77.5] 79 [73–85]*# 83 [78.5–89] 84 [77–89] 0.0001
Body mass index (kg/m2) 25 ± 5 25 ± 4 25 ± 4 24 ± 4 24 ± 4 0.7
SBP at admission (mmHg) 182 ± 27 150 ± 17 150 ± 25 160 ± 22 150 ± 27 0.06
Lowest SBP measured during
admission (mmHg)
107 ± 33 116 ± 17 111 ± 23 111 ± 20 109 ± 20 0.8
PS at admission (%) 94 ± 4 97 ± 3 94 ± 5 94 ± 4 94 ± 4 0.1
TP at admission 37.4 ± 0.7 36.6 ± 0.7 36.8 ± 0.5# 37.1 ± 0.8 36.9 ± 0.6 0.04
Estimated glomerular filtration
rate (ml/min)
51 [6–61] 81.5 [73–88] * 71 [50–86] 75 [47–86] 66 [44–82] 0.04
Sodium (mmol/l) 140 [137–143] 139 [136–141] 140 [138–141]*# 137 [135–141] 138 [136–141] 0.002
Number of drugs at admission 11.6 ± 5.1 – 6.4 ± 4.3* 6.4 ± 3.3* 9.7 ± 4.0 < 0.0001
Number of FRIDS at admission 2.3 ± 1.2 – 2.3 ± 1.4* 1.75 ± 1.3* 3.7 ± 1.2 < 0.0001
Proportion of patients with
PIMs (n (%))
3 (100) – 34 (57) Ɨ 25 (52) Ɨ 79 (96) –
The table shows means ± standard deviations for parametric data and medians [interquartile range] for nonparametric data. Differences in the numeric data
between groups were analysed by regression with a bootstrap analysis; *: p-value < 0.05 vs group 5. #: p-value < 0.05 vs group 4. Differences in the proportion of
patients with PIMs were analysed by pairwise two-sample z-tests among groups 3, 4, and 5; Ɨ: p-value < 0.001 vs group 5. Abbreviations: SBP systolic blood
pressure, PS peripheral saturation, TP temperature, FRIDS Fall-risk-increasing medications, PIMs Potentially inappropriate medications. Number of persons with
missing data for each variable: age: 0, body mass index: 24 (0, 1, 6, 6, and 11 in group 1, 2, 3, 4, and 5, respectively), SBP at admission: 2 (2 in group 5), lowest
blood pressure during admission: 8 (1, 2, and 5 in group 3, 4, and 5, respectively), PS: 4 (4 in group 5), TP: 8 (2 and 6 in group 3 and 5, respectively), estimated
glomerular filtration rate: 1 (1 in group 4), sodium; 2 (1 in group 4 and 5), number of drugs, FRIDs and PIMs: 0
Fig. 2 Medications most commonly suspected of contributing to falls. Figure 2. Drug classes most frequently suspected to contribute to the fall
in patients with a suspected medication-related fall (group 5, Fig. 1). Left axis shows the crude number of patients in which the drug contribute.
Right axis shows the percentage. Abbreviations: SSRI: selective serotonin reuptake inhibitors, ACE: angiotensin-II converting enzyme, AT-II:
angiotensin-II receptor, NaSSa: Noradrenergic and specific serotonergic antidepressants
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seems likely that a medication review followed by with-
drawal of inappropriate medications could have reduced,
though not eliminated, the risk of falling in 74 (37%) of the
total population. Still, intervention studies are warranted
and the present data may support planning of such studies.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12877-020-01532-9.
Additional file 1: Table S1. Medications used at the time of admission
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